Congestive Heart Failure With Rhabdomyolysis and Acute Renal Failure in a Manifesting Female Carrier of Duchenne Muscular Dystrophy With Duplication of Dystrophin Gene

2009 ◽  
Vol 11 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Atchara Tunteeratum ◽  
Rawiphan Witoonpanich ◽  
Suchart Phudhichareonrat ◽  
Jakris Eu-ahsunthornwattana ◽  
Sarinee Pingsuthiwong ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Dystrophin Gene ◽  
Female Carrier

Incidence and Predictors of Development of Acute Renal Failure Related to Treatment of Congestive Heart Failure with ACE Inhibitors

2006 ◽  
Vol 105 (2) ◽  
pp. c77-c83 ◽  
Author(s):  
Constança S. Cruz ◽  
Luzia S. Cruz ◽  
Giulliana R. Silva ◽  
Carlos A. Marcílio de Souza
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Ace Inhibitors

Acute renal failure during nifedipine therapy in a patient with congestive heart failure

1988 ◽  
Vol 16 (11) ◽  
pp. 1163-1164 ◽  
Author(s):  
JEAN C. EICHER ◽  
PATRICE MORELON ◽  
JEAN M. CHALOPIN ◽  
YVES TANTER ◽  
PIERRE LOUIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure

scholarly journals A case of congestive heart failure due to probable peripartum cardiomyopathy complicated by acute renal failure

1988 ◽  
Vol 21 (9) ◽  
pp. 871-875
Author(s):  
Yoshifumi Maruyama ◽  
Hisao Mabuchi ◽  
Takeshi Kakiuchi ◽  
Tadashi Aoki ◽  
Hisamitsu Nakahashi
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Peripartum Cardiomyopathy

Captopril induced reversible acute renal failure in a premature neonate with double outlet right ventricle and congestive heart failure

2010 ◽  
Vol 7 (1) ◽  
pp. 89-91 ◽  
Author(s):  
Lin-Hua Tan ◽  
Li-Zhong Du ◽  
Michael R. Carr ◽  
Julia K. Kuzin ◽  
Brady S. Moffett ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Right Ventricle ◽  
Premature Neonate ◽  
Double Outlet Right Ventricle

scholarly journals PCV18 The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure

1998 ◽  
Vol 1 (1) ◽  
pp. 55
Author(s):  
Y-T Chen ◽  
D Bradford ◽  
Y Wang ◽  
J Seltzer ◽  
H Krumholz
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Elderly Patients ◽  
The Impact

scholarly journals Parvovirus B19-Induced Constellation of Acute Renal Failure, Elevated Aminotransferases and Congestive Heart Failure

1997 ◽  
Vol 8 (1) ◽  
pp. 53-55
Author(s):  
Iain W McAuley ◽  
Farshad Sepandj ◽  
Walter Schlech
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Parvovirus B19 ◽  
Acute Infection ◽  
Subsequent Development ◽  
Organ Involvement ◽  
Serological Evidence ◽  
History Of

This report details a case of acute renal failure and elevated aminotransferases with subsequent development of congestive heart failure in a patient with history of exposure to parvovirus B19 and serological evidence of acute infection with this agent. This constellation of organ involvement has not been previously reported in the literature.

scholarly journals Novel Use of Tolvaptan in a Pediatric Patient With Congestive Heart Failure Due to Duchenne Muscular Dystrophy and Congenital Adrenal Hyperplasia

2015 ◽  
Vol 20 (5) ◽  
pp. 393-396
Author(s):  
Sarah A. Sami ◽  
Brady S. Moffett ◽  
Melissa L. Karlsten ◽  
Antonio G. Cabrera ◽  
Jack F. Price ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Congenital Adrenal Hyperplasia ◽  
Adverse Reactions ◽  
The Novel ◽  
Adrenal Hyperplasia ◽  
Organ Function ◽  
Multifaceted Approach

Successful management of hyponatremia in heart failure patients requires a multifaceted approach in order to preserve end-organ function. We describe the novel use of a selective vasopressin receptor antagonist, tolvaptan, for management of hyponatremia in a 17-year-old Caucasian male with severe Duchenne muscular dystrophy, congestive heart failure (CHF), and congenital adrenal hyperplasia. The medical history was significant for recurrent admissions for hyponatremia secondary to adrenal crises, which was also exacerbated by his CHF. After initiation of tolvaptan and its extended administration, he had no further hyponatremia-related admissions and no adverse reactions. The complexity of this combination of conditions is presented, and the efficacy of the drug and the rationale behind the treatment approach is discussed.

Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure

Renal Failure ◽  
1998 ◽  
Vol 20 (5) ◽  
pp. 717-723 ◽  
Author(s):  
Koichi Seta ◽  
Takahiro Hayashi ◽  
Akira Sugawara ◽  
Kenji Kasuno ◽  
Satoshi Watanabe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Atrial Natriuretic

scholarly journals Early Diagnosis and Treatment – The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy

2018 ◽  
Vol 13 (1) ◽  
pp. 31
Author(s):  
Eugenio Mercuri ◽  
Ros Quinlivan ◽  
Sylvie Tuffery-Giraud
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
De Novo ◽  
Point Mutations ◽  
Dystrophin Gene ◽  
Phase Iii ◽  
Female Carrier ◽  
De Novo Mutations ◽  
Nonsense Mutations ◽  
Disease Modifying

The understanding of the natural history of Duchenne muscular dystrophy (DMD) is increasing rapidly and new treatments are emerging that have the potential to substantially improve the prognosis for patients with this disabling and life-shortening disease. For many, however, there is a long delay between the appearance of symptoms and DMD diagnosis, which reduces the possibility of successful treatment. DMD results from mutations in the large dystrophin gene of which one-third are de novo mutations and two-thirds are inherited from a female carrier. Roughly 75% of mutations are large rearrangements and 25% are point mutations. Certain deletions and nonsense mutations can be treated whereas many other mutations cannot currently be treated. This emphasises the need for early genetic testing to identify the mutation, guide treatment and inform genetic counselling. Treatments for DMD include corticosteroids and more recently, ataluren has been approved in Europe, the first disease-modifying therapy for treating DMD caused by nonsense mutations. The use of ataluren in DMD is supported by positive results from phase IIb and phase III studies in which the treatment produced marked improvements in the 6-minute walk test, timed function tests such as the 10 m walk/run test and the 4-stair ascent/descent test compared with placebo. In these trials, ataluren was well tolerated and adverse event profiles were similar to placebo. As such disease-modifying treatments become more widely available, the outlook for children with DMD will improve but physicians must be aware of the disease, rapidly initiate testing where it is suspected and promptly begin appropriate treatment.

Sign in / Sign up

Export Citation Format

Share Document